Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimers, and methods and uses of the dendrimers in therapy of disorders such as cancers. Processes for making the dendrimers and intermediates are also provided.

A modified conjugated diene-based polymer containing: having a weight average molecular weight of 20×10.sup.4 or more and 300×10.sup.4 or less, having a star-branched structure with a conjugated diene-based polymer chain bonded to a modifier residue, wherein the modifier residue has at least 4 silicon atoms, and alkoxy groups and/or hydroxyl groups and the conjugated diene-based polymer chain is bonded to the silicon atom, wherein the number of alkoxy groups and/or hydroxyl groups in the modifier residue is larger than the number of the silicon atoms on average.

Described herein are associative polymers capable of controlling one or more physical and/or chemical properties of non-polar compositions and related compositions, methods and systems.

A catalytic cracking process includes a step of contacting a cracking feedstock with a catalytic cracking catalyst in the presence of a radical initiator for reaction under catalytic cracking conditions. The radical initiator contains a dendritic polymer and/or a hyperbranched polymer. The dendritic polymer and the hyperbranched polymer each independently has a degree of branching of about 0.3-1, and each independently has a weight average molecular weight of greater than about 1000. The catalytic cracking process is beneficial to enhancing and accelerating the free radical cracking of petroleum hydrocarbon and promoting the regulation of cracking activity and product distribution; by using the process disclosed herein, the conversion of catalytic cracking can be improved, the yields of ethylene and propylene can be increased, and the yield of coke can be reduced.

The present invention relates to a composite having exceptional heat resistance and durability that exhibits quick response characteristics when used in an electrochromic device; an electrochromic device in which the composite is used; and a method for producing said composite and device. This composite contains an organic/metallic hybrid polymer that contains an organic ligand and a metal ion coordinated to the organic ligand, and an ionic liquid. The organic/metallic hybrid polymer forms ionic bonds with the ionic liquid. This electrochromic device comprises a first electrode, an electrochromic layer containing the composite, an electrolyte layer, and a second electrode.

Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimers, and methods and uses of the dendrimers in therapy of disorders such as cancers. Processes for making the dendrimers and intermediates are also provided.

The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.

A contact lens with sustained-release property is provided. The contact lens includes a polymer, pseudorotaxane embedded in the polymer, and a stabilizer embedded in the pseudorotaxane. The polymer is polymerized by monomer materials. The monomer materials include ethyl methacrylate, ethylene glycol dimethacrylate, methacrylic acid, 2-hydroxyethyl methacrylate, or a combination thereof. The stabilizer includes surfactant, amino acid with a polar side chain, oligopeptide containing at least one amino acid with a polar side chain, purine or its derivative, or a combination thereof.

Core-shell particles and methods of making and using thereof are described herein. The core is formed of or contains one or more hydrophobic materials or more hydrophobic materials. The shell is formed of or contains hyperbranched polyglycerol (HPG). The HPG coating can be modified to adjust the properties of the particles. Unmodified HPG coatings impart stealth properties to the particles which resist non-specific protein absorption and increase circulation in the blood. The hydroxyl groups on the HPG coating can be chemically modified to form functional groups that react with functional groups and adhere the particles to tissue, cells, or extracellular materials, such as proteins.

Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.g., ingestion of a solution that induces rapid dissolution/degradation). In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance (e.g., a therapeutic agent), and, optionally, a linker. In some such embodiments, the linker may be configured to degrade such that the residence structure breaks apart and is released from the location internally of the subject after a predetermined amount of time.